http://159.195.202.159:8091/blog/media-release/shilpa-medicare-backs-us-biotech-alveolus-bio-to-accelerate-next-gen-lung-disease-therapies/2026-06-13T15:22:38+05:30http://159.195.202.159:8091/blog/media-release/launch-of-2nd-nda-bortezomib-for-injection3-5mg-1-4ml-in-us/2026-06-13T15:22:48+05:30http://159.195.202.159:8091/blog/media-release/us-approval-for-varenicline-tablets-0-5-mg-and-1-mg/2026-06-13T15:22:49+05:30http://159.195.202.159:8091/blog/media-release/europe-ages-austria-inspection-of-shilpa-biologicals-pvt-ltd-sbpl-a-wholly-owned-subsidiary-of-sml/2026-06-13T15:22:51+05:30http://159.195.202.159:8091/blog/media-release/approval-by-european-medicines-agency-for-shilpa-medicare-ltd/2026-06-13T15:22:55+05:30http://159.195.202.159:8091/blog/media-release/shilpa-pharma-lifesciences-limited-unit-1-received-eir-from-usfda/2026-06-13T15:22:57+05:30http://159.195.202.159:8091/blog/media-release/eir-from-usfda-for-shilpa-medicare-ltd-unit-vi-bengaluru/2026-06-13T15:23:00+05:30http://159.195.202.159:8091/blog/media-release/initial-authorization-for-rivaroxaban-orodispersible-films-from-europe/2026-06-13T15:23:02+05:30http://159.195.202.159:8091/blog/media-release/initial-authorization-for-rivaroxaban-orodispersible-films-from-europstake-sale-in-sravathi-advance-process-technologies/2026-06-13T15:23:05+05:30http://159.195.202.159:8091/blog/media-release/shilpa-biologicals-pvt-ltd-signs-strategic-development-partnership-with-mabtree-biologics-ag-for-a-novel-immunooncology-asset/2026-06-13T15:23:06+05:30http://159.195.202.159:8091/blog/media-release/clinical-trial-announcement-for-sml-007/2026-06-13T15:23:08+05:30http://159.195.202.159:8091/blog/media-release/eurasia-eaeu-gmp-approval-of-shilpa-medicare-ltd-unit-iv-jadcherla-telangana-and-unit-vii/2026-06-13T15:23:10+05:30http://159.195.202.159:8091/blog/media-release/europe-approval-for-tadalafil-orodisperible-films/2026-06-13T15:23:12+05:30http://159.195.202.159:8091/blog/media-release/europe-gmp-approval-of-shilpa-medicare-ltd-unit-4-jadcherla-telangana/2026-06-13T15:23:14+05:30http://159.195.202.159:8091/blog/media-release/important-milestone-for-the-cdmo-business-of-sml/2026-06-13T15:23:16+05:30http://159.195.202.159:8091/blog/media-release/indian-regulatory-authority-sec-approval-for-conducting-phase-iii-clinical-trials-for-recombinant-human-albumin-rha-20/2026-06-13T15:23:17+05:30http://159.195.202.159:8091/blog/media-release/shilpa-biologicals-pvt-ltd-signs-strategic-development-partnership-with-mabtree-biologics-ag-for-a-novel-immuno-onco-asset/2026-06-13T15:23:19+05:30http://159.195.202.159:8091/blog/media-release/shilpa-medicare-announces-acceptance-by-usfda-of-nda-filed-by-its-cdmo-partner-unicycive-olc/2026-06-13T15:23:21+05:30http://159.195.202.159:8091/blog/media-release/shilpa-pharma-lifesciences-limited-received-cep-from-edqm-for-api-desmopressin/2026-06-13T15:23:24+05:30http://159.195.202.159:8091/blog/media-release/shilpa-pharma-lifesciences-limited-received-cep-from-edqm-for-api-nifedipine/2026-06-13T15:23:25+05:30http://159.195.202.159:8091/blog/media-release/shilpa-pharma-lifesciences-limited-received-cep-from-edqm-for-api-octreotide/2026-06-13T15:23:27+05:30http://159.195.202.159:8091/blog/media-release/shilpa-pharma-lifesciences-limited-received-cep-from-edqm-for-api-teriflunomide/2026-06-13T15:23:28+05:30http://159.195.202.159:8091/blog/media-release/shilpa-pharma-lifesciences-limited-received-cep-from-edqm-for-api-ursodeoxycholic-acid/2026-06-13T15:23:30+05:30http://159.195.202.159:8091/blog/media-release/shilpa-pharma-lifesciences-limited-unit-2-raichur-karnataka-has-cleared-the-anvisa-brazil-gmp-inspection/2026-06-13T15:23:32+05:30http://159.195.202.159:8091/blog/media-release/smls-cdmo-customer-receives-fast-track-designation-for-its-investigational-drug-candidate/2026-06-13T15:23:34+05:30http://159.195.202.159:8091/blog/media-release/unit-2-raichur-karnataka-has-cleared-the-cofepris-mexico-gmp/2026-06-13T15:23:35+05:30http://159.195.202.159:8091/blog/media-release/usfda-approval-of-nda-imkeldi-imatinib-oral-solution-filled-by-our-partner-shorla-oncology/2026-06-13T15:23:37+05:30http://159.195.202.159:8091/blog/media-release/acquisition-of-pilnova-pharma-inc-a-wholly-owned-subsidiary/2026-06-13T15:23:39+05:30http://159.195.202.159:8091/blog/media-release/approval-by-tga-australia-for-shilpa-medicare-ltd-unit-vi-bengaluru/2026-06-13T15:23:40+05:30http://159.195.202.159:8091/blog/media-release/europe-approval-for-amifampridine-tablets-10-mg/2026-06-13T15:23:42+05:30http://159.195.202.159:8091/blog/media-release/europe-approval-for-varenicline-tablets-0-5mg-and-1mg/2026-06-13T15:23:43+05:30http://159.195.202.159:8091/blog/media-release/marketing-authorization-for-adalimumab-40-mg-0-4-ml-injection/2026-06-13T15:23:45+05:30http://159.195.202.159:8091/blog/media-release/shilpa-medicare-limited-launches-lenvatinib-capsules-12mg-18mg-24-mg-in-india-under-the-brand-name-lenshil/2026-06-13T15:23:47+05:30http://159.195.202.159:8091/blog/media-release/shilpa-medicare-limited-receives-us-fda-approval-for-psoriatic-arthritis-drug/2026-06-13T15:23:48+05:30http://159.195.202.159:8091/blog/media-release/shilpa-medicare-limited-analytical-services-division-unit-7-nacharam-hyderabad-us-fda-gmp/2026-06-13T15:23:49+05:30http://159.195.202.159:8091/blog/media-release/shilpa-medicare-ltd-unit-iv-jadcherla-telangana-has-cleared-anvisa-brazil-gmp-inspection/2026-06-13T15:23:50+05:30http://159.195.202.159:8091/blog/media-release/shilpa-pharma-lifesciences-ltd-unit-ii-raichur-karnataka-has-cleared-pmda-japan-gmp-inspection/2026-06-13T15:23:52+05:30http://159.195.202.159:8091/blog/media-release/stake-sale-of-4-of-its-stake-held-in-sravathi-advance-process-technologies-private-limited/2026-06-13T15:23:53+05:30http://159.195.202.159:8091/blog/media-release/shilpa-biocare-a-wholly-owned-subsidiary-of-shilpa-medicare-enters-into-a-strategic-partnership-with-orion-corporation-orion-finland/2026-06-13T15:25:25+05:30http://159.195.202.159:8091/blog/media-release/shilpa-biologics-pvt-ltd-sbpl-receives-first-international-market-approval-for-adalimumab-40-mg-in-morocco/2026-06-13T15:25:26+05:30http://159.195.202.159:8091/blog/media-release/shilpa-medicare-announces-successful-outcome-of-phase-3-studies-of-smlnud07-norudca/2026-06-13T15:25:28+05:30http://159.195.202.159:8091/blog/media-release/grant-of-code-j-for-pemetrexed-injection-100mg-10-ml-500-mg-50-ml-1000-mg-100-ml/2026-06-13T15:25:28+05:30http://159.195.202.159:8091/blog/media-release/uk%e2%80%90mhra-approval-for-betahistine-dihydrochloride-orodispersible-films-24-mg/2026-06-13T15:25:29+05:30http://159.195.202.159:8091/blog/media-release/shilpa-medicare-limited-division-onkoshil-mrp-gst-rate-change-compliance-with-dpco/2026-06-13T15:25:33+05:30